Immune regulation and timing of chemotherapy in advanced/recurrent ovarian cancer to evaluate tumour response

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000013369

Enrollment

Registered

2008-01-10

Start date

2008-03-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We have shown that the immune system regulates itself on an approximately 2 week basis.By killing the inhibitory immune cells that prevent immune attack on the tumour using low dose oral chemotherapy it is hoped that tumour cells will die and responses achieved

Interventions

Synchronised chemotherapy using cyclophosphamide 100 mg orally for 3 days each 2 week cycle for at least 3 cycles

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

Rising CA125 (Rustin) 2 previous lines of chemotherapy

Exclusion criteria

Impending bowel obstruction

Outcome results